US Broker Ratings

LivaNova PLC (LIVN) Stock Analysis: Potential 30% Upside Amid Strong Buy Ratings

LivaNova PLC (NASDAQ: LIVN), a prominent player in the healthcare sector specializing in medical devices, is capturing the attention of investors with its robust 30.08% potential upside, as indicated by..

Privia Health Group, Inc. (PRVA) Investor Outlook: A Promising 45% Upside with Strong Buy Ratings

Privia Health Group, Inc. (NASDAQ: PRVA) is making waves in the healthcare sector, particularly within the health information services industry. With a market capitalization of $2.72 billion, this Arlington, Virginia-based..

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Analyst Consensus Points to a Promising 42.66% Upside

Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a Canadian biotechnology company specializing in neuroscience, has captured investor attention with its robust pipeline and impressive analyst ratings. As a biopharmaceutical firm, Xenon is..

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring a 129% Potential Upside in the Healthcare Sector

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is attracting significant attention within the healthcare sector, particularly among those invested in the dynamic world of biotechnology. With a market cap of $2.33 billion,..

Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: A Biotech Gem with a 45.92% Upside Potential

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) stands out as a compelling investment opportunity within the biotechnology sector, attracting attention with its robust growth prospects and significant potential upside. Headquartered in Coral..

Envista Holdings Corporation (NVST): Investor Outlook on a 13.76% Potential Upside

Envista Holdings Corporation (NYSE: NVST) stands out in the healthcare sector, specifically in the medical instruments and supplies industry. With a market capitalization of $4.11 billion, Envista has carved a..

Viking Therapeutics, Inc. (VKTX)

⚠️ No article content returned.

..

MoonLake Immunotherapeutics (MLTX) Stock Analysis: A Biotech Contender with 42.60% Upside Potential

MoonLake Immunotherapeutics, trading under the stock symbol MLTX, is emerging as a notable player in the biotechnology industry. Headquartered in Zug, Switzerland, this clinical-stage biotech company is focused on developing..

Sotera Health Company (SHC) Stock Analysis: Unpacking a 52.91% Potential Upside for Investors

Sotera Health Company (NASDAQ: SHC) stands as a compelling opportunity in the healthcare sector, particularly for investors seeking growth in the Diagnostics & Research industry. With a market capitalization of..

Krystal Biotech, Inc. (KRYS) Stock Analysis: Key Insights into Its 26.68% Potential Upside

Krystal Biotech, Inc. (NASDAQ: KRYS) has emerged as a significant player in the biotechnology sector, with a market capitalization of $7.23 billion. Specializing in genetic medicines for treating diseases with..

Atrium Therapeutics, Inc. (RNA) Stock Analysis: Unlocking an 81.82% Potential Upside in the Biotech Sector

Atrium Therapeutics, Inc. (NASDAQ: RNA) is capturing the attention of investors with its innovative approach to RNA-based therapies, particularly targeting cardiomyopathies. The company specializes in developing small interfering RNA (siRNA)..

Integer Holdings Corporation (ITGR): Investor Outlook and Potential 12.38% Upside

Integer Holdings Corporation (NYSE: ITGR) stands as a noteworthy player in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $2.91 billion, this American company..

Oscar Health, Inc. (OSCR) Stock Analysis: A 16.40% Potential Upside Amidst Revenue Growth

For investors navigating the labyrinth of healthcare stocks, Oscar Health, Inc. (NYSE: OSCR) presents a compelling, albeit complex, opportunity. With a market capitalization of $3.94 billion, Oscar Health stands out..

Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing a 15% Upside as Healthcare Innovations Lead

Bausch + Lomb Corporation (NYSE: BLCO) stands out in the healthcare sector as a venerable player within the medical instruments and supplies industry. With a rich history dating back to..

Charles River Laboratories (CRL) Stock Analysis: Exploring the 27% Upside Potential

Charles River Laboratories International, Inc. (NYSE: CRL) presents a compelling opportunity for investors intrigued by the healthcare sector’s diagnostics and research segment. With a market capitalization of $7.65 billion, this..

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: An Investor Outlook with a Staggering 218% Potential Upside

Soleno Therapeutics, Inc. (SLNO), a biopharmaceutical firm based in Redwood City, California, is drawing significant attention from investors, both for its innovative approach to treating rare diseases and its impressive..

Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A Biotech Powerhouse with 42.53% Potential Upside

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is capturing investor attention with a compelling potential upside of 42.53%, making it a standout in the biotechnology sector. This New York-based biopharmaceutical company specializes..

Globus Medical, Inc. (GMED) Stock Analysis: A 28.95% Potential Upside Beckons Investors

Globus Medical, Inc. (NASDAQ: GMED), a formidable player in the healthcare sector, specifically within the medical devices industry, is presenting an intriguing opportunity for investors with its potential 28.95% upside...

Alkermes plc (ALKS) Stock Analysis: Evaluating a 57% Upside Potential

Alkermes plc (NASDAQ: ALKS), an Ireland-based biopharmaceutical company, stands out in the healthcare sector with its diversified portfolio of pharmaceutical products targeting unmet medical needs. With a market capitalization of..

DaVita Inc. (DVA) Stock Analysis: Evaluating the Healthcare Giant’s 64.85% ROE and Future Potential

DaVita Inc. (NYSE: DVA), a stalwart in the healthcare sector, operates at the forefront of providing essential kidney dialysis services across the United States. With a market capitalization of $10.08..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds